JPS6363553B2 - - Google Patents
Info
- Publication number
- JPS6363553B2 JPS6363553B2 JP6522781A JP6522781A JPS6363553B2 JP S6363553 B2 JPS6363553 B2 JP S6363553B2 JP 6522781 A JP6522781 A JP 6522781A JP 6522781 A JP6522781 A JP 6522781A JP S6363553 B2 JPS6363553 B2 JP S6363553B2
- Authority
- JP
- Japan
- Prior art keywords
- medium
- xylopyranoside
- present
- xylopyranosylamine
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NSDHOPYJPQTFRO-SMRSKGNSSA-N C1=CC(C(=O)N)=CC=C1NC1[C@H](O)[C@@H](O)[C@H](O)CO1 Chemical compound C1=CC(C(=O)N)=CC=C1NC1[C@H](O)[C@@H](O)[C@H](O)CO1 NSDHOPYJPQTFRO-SMRSKGNSSA-N 0.000 claims description 9
- 239000002609 medium Substances 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 11
- 229920002683 Glycosaminoglycan Polymers 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 8
- 229920001287 Chondroitin sulfate Polymers 0.000 description 8
- 229940059329 chondroitin sulfate Drugs 0.000 description 8
- 102000016611 Proteoglycans Human genes 0.000 description 7
- 108010067787 Proteoglycans Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RQBSUMJKSOSGJJ-IOVATXLUSA-N (3r,4s,5r)-2-aminooxane-3,4,5-triol Chemical compound NC1OC[C@@H](O)[C@H](O)[C@H]1O RQBSUMJKSOSGJJ-IOVATXLUSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- QIKYZXDTTPVVAC-UHFFFAOYSA-N 4-Aminobenzamide Chemical compound NC(=O)C1=CC=C(N)C=C1 QIKYZXDTTPVVAC-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- -1 xyloside compound Chemical class 0.000 description 2
- 150000008216 xylosides Chemical class 0.000 description 2
- GPZFMLHWAOXYHM-GZBOUJLJSA-N 1-phenyl-1-[(3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]urea Chemical compound C=1C=CC=CC=1N(C(=O)N)C1OC[C@@H](O)[C@H](O)[C@H]1O GPZFMLHWAOXYHM-GZBOUJLJSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6522781A JPS57183798A (en) | 1981-05-01 | 1981-05-01 | N-p-carbamoylphenyl-d-xylopyranosylamine |
| DE8484100498T DE3176380D1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| EP84100498A EP0117413B1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| EP81110216A EP0053827B1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| DE8484100499T DE3176465D1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| EP84100499A EP0118676B1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| DE8181110216T DE3172379D1 (en) | 1980-12-09 | 1981-12-07 | D-xylopyranoside series compounds and therapeutical compositions containing same |
| US06/472,786 US4454123A (en) | 1980-12-09 | 1983-03-07 | O-xylopyranoside series compounds and methods of use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6522781A JPS57183798A (en) | 1981-05-01 | 1981-05-01 | N-p-carbamoylphenyl-d-xylopyranosylamine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57183798A JPS57183798A (en) | 1982-11-12 |
| JPS6363553B2 true JPS6363553B2 (https=) | 1988-12-07 |
Family
ID=13280815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6522781A Granted JPS57183798A (en) | 1980-12-09 | 1981-05-01 | N-p-carbamoylphenyl-d-xylopyranosylamine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57183798A (https=) |
-
1981
- 1981-05-01 JP JP6522781A patent/JPS57183798A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57183798A (en) | 1982-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0117413B1 (en) | D-xylopyranoside series compounds and therapeutical compositions containing same | |
| US5070079A (en) | Pharmaceutical compositions containing cytidine monophosphate of 5-acetamido-3-, 5-d-deoxy-d-glycero-d-galacto-nonulosamic acid | |
| MXPA06013513A (es) | Nuevos derivados fluoroglicosidicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos. | |
| EP0052340B1 (en) | C-beta-d-xylopyranoside series compounds and pharmaceutical compositions containing them | |
| CA1181393A (en) | Processes for the manufacture of derivatives of aldohexoses | |
| CN115785070B (zh) | 一种吡咯烷基乙酰胺衍生物、制备方法及其应用 | |
| EP0176068B1 (de) | Verfahren zur Herstellung der Stereoisomeren von 1-Amino-alkylphosphonsäuren oder 1-Amino-alkylphosphinsäuren | |
| US3864325A (en) | (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives | |
| IE55838B1 (en) | Novel muramyl peptides and processes for their manufacture | |
| JPS6363553B2 (https=) | ||
| EP0162715A2 (en) | Enzyme-inhibitory griseolic acid derivatives, and their use | |
| EP3978506B1 (en) | Antibacterial aminoglycoside derivatives | |
| Austin et al. | The Preparation of Two New Crystalline Aldohexoses, l-Allose and l-Altrose, from l-Ribose by the Cyanohydrin Reaction1, 2, 3 | |
| RU2852851C1 (ru) | Способ синтеза субстанции аранозы (3-(α-L-арабинопиранозил-1)-1-метил-1-нитрозомочевины) фармакопейного качества | |
| JPS6361308B2 (https=) | ||
| US4990500A (en) | Oxirane pseudooligosaccharides, a process for their preparation, their use and pharmaceutical preparations | |
| AU2017405304B2 (en) | Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses | |
| JPH0136833B2 (https=) | ||
| JP2854705B2 (ja) | 新規モラノリン誘導体およびその製造法 | |
| EP2668198A1 (en) | Fgf receptor-activating 3-o-alkyl oligosaccharides, preparation thereof and therapeutic use thereof | |
| JPH05178876A (ja) | 抗炎症・抗アレルギー作用を有するオリゴ糖誘導体 | |
| US20170152279A9 (en) | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | |
| JPH0128750B2 (https=) | ||
| US3142672A (en) | Derivatives of nu-alpha-phenyl-and nu-alpha-biphenylylbutyric acids and amino sugars | |
| HK40072348A (en) | Antibacterial aminoglycoside derivatives |